Jazz Pharmaceuticals to Participate in Upcoming Investor Events

Core Insights - Jazz Pharmaceuticals will participate in key investor events in January 2026, including a webcast to review Phase 3 trial results for zanidatamab [1][2] Group 1: Upcoming Events - The company will host an investor webcast on January 9, 2026, at 6:30 a.m. PT / 3:30 p.m. GMT to discuss results from the Phase 3 zanidatamab HERIZON-GEA-01 trial, featuring commentary from senior management and Dr. Geoffrey Ku [1] - Jazz Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 11:15 a.m. PST / 7:15 p.m. GMT, where CEO Renee Gala will provide a company strategy overview and business update [2] Group 2: Company Overview - Jazz Pharmaceuticals is a global biopharma company focused on developing innovative medicines for serious diseases, with a diverse portfolio that includes therapies for sleep disorders, epilepsy, and cancer treatments [3] - The company is headquartered in Dublin, Ireland, and has research and development laboratories, manufacturing facilities, and employees in multiple countries dedicated to serving patients worldwide [3]